Nimotuzumab is different than cetuximab and panitumumab in SCCHN #hncs16

Nimotuzumab is different than cetuximab and panitumumab in SCCHN #hncs16

User Photo
ASTROHN2016

4 years
390 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Ezra Cohen, MD of the University of California at San Diego discusses how the EGFR monoclonal antibody, Nimotuzumab, differ from cetuximab and panitumumab and If it's likely to play a therapeutic role in SCCHN at ASTRO Head and Neck Symposium 2016.
Up Next Autoplay
>